FP802 dihydrochloride

FP802 hydrochloride 是一种口服有效的强效 TwinF 界面抑制剂,可破坏并解除 NMDAR/TRPM4 死亡复合物的毒性;在 5xFAD 阿尔茨海默病 (AD) 小鼠模型中,它发挥强大的神经保护作用,可防止认知功能衰退、维持神经元结构完整性、减少 β- 淀粉样蛋白斑块形成并减轻线粒体病变,而在肌萎缩侧索硬化 (ALS) 小鼠模型中,它能阻止运动神经元丢失、降低血清神经丝轻链 (NfL) 水平、改善运动表现并延长小鼠寿命,因此可用于阿尔茨海默病和肌萎缩侧索硬化症的相关研究。
产品编号: MS-K73430 纯度: 99.84% CAS No.: 2490401-57-3 分子式: C11H19Cl3N2 分子量: 285.64
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
3-5 天
100mg
询价
3-5 天
200mg
询价
询价
500mg
询价
询价

产品描述

FP802 hydrochloride 是一种口服有效的强效 TwinF 界面抑制剂,可破坏并解除 NMDAR/TRPM4 死亡复合物的毒性;在 5xFAD 阿尔茨海默病 (AD) 小鼠模型中,它发挥强大的神经保护作用,可防止认知功能衰退、维持神经元结构完整性、减少 β- 淀粉样蛋白斑块形成并减轻线粒体病变,而在肌萎缩侧索硬化 (ALS) 小鼠模型中,它能阻止运动神经元丢失、降低血清神经丝轻链 (NfL) 水平、改善运动表现并延长小鼠寿命,因此可用于阿尔茨海默病和肌萎缩侧索硬化症的相关研究。

生物实验数据

生物活性 FP802 hydrochloride is an orally effective potent TwinF interface inhibitor that disrupts and detoxicates the NMDAR/TRPM4 death complex; in the 5xFAD Alzheimer's disease (AD) mouse model, it exerts robust neuroprotective effects by preventing cognitive decline, maintaining neuronal structural integrity, reducing β-amyloid plaque formation, and alleviating mitochondrial pathology, while in the amyotrophic lateral sclerosis (ALS) mouse model, it prevents motor neuron loss, lowers serum neurofilament light chain (NfL) levels, improves motor performance, and extends mouse lifespan, and is therefore useful for research related to Alzheimer's disease and amyotrophic lateral sclerosis.
体外研究
(In Vitro)

FP802 (8 μM,24-72 小时) hydrochloride 能有效破坏 NMDAR/TRPM4 复合物并在细胞模型中提供神经保护,但它本身并不直接促进或抑制神经突的生长。
FP802 (10 μM,30 分钟) hydrochloride 表现出强大的神经保护作用,可抵抗谷氨酸 (20 μM) 介导的毒性 (IC50 = 8.7 µM),并将 NMDA 抑制的即刻早期基因表达恢复到生理水平。
FP802 hydrochloride 在 HEK293 细胞中对 NMDAR 未显示拮抗活性 (GluN1/GluN2A 和 GluN1/GluN2B 的 IC50 均 > 250 mM)。
FP802 (30 分钟) hydrochloride 能够剂量依赖性地阻断 NMDA 诱导的散发性 ALS 疾病特异性诱导多能干细胞 (iPSCs) 来源前脑类器官中神经元的有丝分裂后死亡。

Real Time qPCR

Cell Line: mouse cortical neurons
Concentration: 10 μM
Incubation Time: 30 min
Result: Eliminated the transcriptional shut-off induced by eNMDARs and boosted the NMDA bath application-induced expression of the immediate-early genes (IEGs) Atf3, Arc, Bdnf, cFos, Inhibin beta A, and Npas4 to reach levels that were comparable to those achieved by Bicuculline (MS-A54336)-induced action potential bursting.
体内研究
(In Vivo)

FP802 (10 和 40 mg/kg,口服,每日一次,持续 4 个月) dihydrochloride 可改善 5xFAD 小鼠的认知功能、防止神经元结构退化并减少淀粉样蛋白病理。
FP802 (40 mg/kg,皮下注射,每日一次,约第 15 周起持续 4 周) dihydrochloride 通过靶向 NMDAR/TRPM4 复合物,能够安全地阻止 ALS 小鼠运动神经元退化并延长其生存期。

Animal Model: 5xFAD transgenic mice and wild-type littermates
Dosage: 10 and 40 mg/kg
Administration: p.o., daily for 4 months
Result: Showed no apparent adverse effects on the liver, kidney, or heart.
Reduced the complex formation of GluN2B with TRPM4 in the 5xFAD mice at both 10 and 40 mg/kg.
Reduced complex formation of GluN2A with TRPM4 at 40 mg/kg.
Significantly decreased the interaction between NMDAR and TRPM4 without affecting the total protein levels of GluN2A, GluN2B, or TRPM4.
Led to a significant increase in the time 5xFAD mice spent in the target quadrant and the frequency with which they crossed the platform's prior location at the dose of 40 mg/kg, compared to vehicle.
Increased the time 5xFAD mice spent exploring the novel object in the Novel Object Recognition (NOR) test and the displaced object in the Novel Location Recognition (NLR) test relative to vehicle treatment.
Prevented the shift of mitochondrial morphologies from normal to pathological phenotypes in both CA1 and CA3.
Effectively preserved dendritic trees in 5xFAD mice as compared to controls, as demonstrated by increased total dendritic length and numbers of crossings in the Sholl analysis.
Prevented the increase in the density of 'apparent orphaned synapses' in both stratum oriens (CA1 basal dendrites) and stratum radiatum (CA1 apical dendrites) of 5xFAD mice.
Prevented the loss of excitatory and inhibitory synapses and the associated structural deterioration of postsynaptic densities (PSD) in the basal and apical dendrites of CA1 neurons, thereby preserving synaptic integrity in 5xFAD mice.
Led to a 25-40% reduction in Aβ plaque load, significantly limiting plaque development without completely preventing its formation.
Animal Model: Male SOD1G93A transgenic mice and wild-type littermates
Dosage: 40 mg/kg
Administration: s.c., daily from ~week 15 for 4 weeks
Result: Disrupted he interaction of TRPM4 with the NMDAR subunit GluN2B in mice spinal cord.
Significantly better neurological scores and less body weight loss than vehicle-treated controls.
Significantly improved motor performance (increased total distance traveled and rearing frequency in the open field).
Significantly extended the lifespan of SOD1G93A mice (survival median increased from 151 to 164 days).
Preserved larger soma sizes of lumbar spinal motor neurons compared to the control group at week 19.
Significantly reduced serum NfL levels while showing no effect on spinal microglial response or EAAT2 expression.
Showed no adverse effects on liver, kidney, heart, or blood counts.
性状 固体
颜色 White to off-white

化学信息

分子量 285.64
分子式 C11H19Cl3N2
CAS No. 2490401-57-3

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

H2O 中的溶解度 : 116.67 mg/mL (408.45 mM; 超声助溶)

可选溶剂浓度1 mg5 mg10 mg25 mg
H2O1 mM3.5009 mL17.5046 mL35.0091 mL87.5228 mL
5 mM0.7002 mL3.5009 mL7.0018 mL17.5046 mL
10 mM0.3501 mL1.7505 mL3.5009 mL8.7523 mL
15 mM0.2334 mL1.1670 mL2.3339 mL5.8349 mL
20 mM0.1750 mL0.8752 mL1.7505 mL4.3761 mL
25 mM0.1400 mL0.7002 mL1.4004 mL3.5009 mL
30 mM0.1167 mL0.5835 mL1.1670 mL2.9174 mL
40 mM0.0875 mL0.4376 mL0.8752 mL2.1881 mL
50 mM0.0700 mL0.3501 mL0.7002 mL1.7505 mL
60 mM0.0583 mL0.2917 mL0.5835 mL1.4587 mL
80 mM0.0438 mL0.2188 mL0.4376 mL1.0940 mL
100 mM0.0350 mL0.1750 mL0.3501 mL0.8752 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础